Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.
Evgen will supply SFX-01 but will not have to foot the bill for the trial. Grant funding has to be obtained, though. There are a significant number of sufferers of fatty liver disease with possibly 40 million people in the US and Europe suffering from the more extreme form the clinical trial would be designed to treat.
The commercial rights will be retained by Evgen. This is positive news following the disappointment of the company’s own clinical trials for the treatment of strokes. Evgen is involved in clinical trials for its own breast cancer treatment using SFX-01.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Aeorema Communications is being hit be the postponement of events.
Walcom Group is short of cash and the chief executive has been unable to provide the funds he intended to lend to the company.
Broadcast software provider Pebble Beach Systems has delayed its 2019 figures due to COVID-19.